91619-38-4

Usage

Uses

Used in Pharmaceutical Industry:
3-(1-Pyrrolidinylsulfonyl)aniline is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the development of new drugs and improve existing ones.
Used in Organic Compounds Synthesis:
In the field of organic chemistry, 3-(1-Pyrrolidinylsulfonyl)aniline is utilized as an intermediate for the synthesis of a range of organic compounds, enhancing the diversity and complexity of chemical structures that can be achieved.
Used in Chemical Research and Development:
3-(1-Pyrrolidinylsulfonyl)aniline plays a significant role in chemical research and development, where it is employed to explore new chemical reactions, mechanisms, and properties, contributing to the advancement of chemical knowledge and technology.

InChI:InChI=1/C10H14N2O2S/c11-9-4-3-5-10(8-9)15(13,14)12-6-1-2-7-12/h3-5,8H,1-2,6-7,11H2

Upstream product

• 121-51-7 3-nitrobenzenesulphonyl chloride 
• 91619-30-6 1-(3-nitrophenylsulfonyl)pyrrolidine 

Downstream Products

• 729578-92-1 2-chloro-N-[3-(pyrrolidinyl-1-sulfonyl)phenyl]acetamide 
• 1443437-95-3 C₂₅H₂₅F₆N₃O₄S 
• 372095-24-4 N-[3-(pyrrolidinylsulfonyl)phenyl]-(2-chloro-5-nitrophenyl)carboxamide 

Relevant academic research and scientific papers

BENZENESULFONAMIDE DERIVATIVES AS TRAP1 MODULATORS AND USES THEREOF

The present disclosure provides compounds of Formula (I): and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled compounds, and prodrugs thereof. The provided compounds may be tumor necrosis factor ("TNF") receptor associated protein 1 ("TRAP1") modulators (e.g., TRAP1 activators). The provided compounds may also rescue the activity in PTEN-induced kinase 1 ("PINK1") loss of function contexts. The provided compounds may also improve mitochondrial health, function, quality, quantity, and/or activity, and/or reduce the production of reactive oxygen species. The provided compounds may also refold or solubilize aggregated or misfolded proteins such as α-synuclein. The present disclosure also provides pharmaceutical compositions comprising the provided compounds; kits comprising the provided compounds or pharmaceutical compositions; and methods of using the provided compounds and pharmaceutical compositions (e.g., for treating a disease in a subject in need thereof).

High-Throughput Screening and Hit Validation of Extracellular-Related Kinase 5 (ERK5) Inhibitors

The extracellular-related kinase 5 (ERK5) is a promising target for cancer therapy. A high-throughput screen was developed for ERK5, based on the IMAP FP progressive binding system, and used to identify hits from a library of 57-617 compounds. Four distinct chemical series were evident within the screening hits. Resynthesis and reassay of the hits demonstrated that one series did not return active compounds, whereas three series returned active hits. Structure-activity studies demonstrated that the 4-benzoylpyrrole-2-carboxamide pharmacophore had excellent potential for further development. The minimum kinase binding pharmacophore was identified, and key examples demonstrated good selectivity for ERK5 over p38α kinase.

Synthesis and anticandidal activity of azole-containing sulfonamides

Twenty five benzenesulfonamides containing one imidazole or triazole ring, or two imidazole or triazole rings have been synthesized and evaluated as anticandidal agents. The most active compounds were 5c, 6b, 6c, 6e, and 17b, which exhibited MIC values of 4.55-24.39 mM depending on the clinical isolate. Comparing imidazole to triazole derivatives did not show a clear effect on activity. Compounds containing a N-benzyl group also showed no clear evidence on activity given the fact that they have an extra aromatic ring. Secondary sulfonamides, 5l, 5m, and 5n showed activities that were proportional to their lipophilicity. The activities of N-aryl-substituted derivatives 5j, 5k, 5l, 5m, 5n, and 6j were also proportional to their lipophilicity. Halogenation enhanced the activity as a result of improvement of lipophilicity. The presence of two imidazole or triazole rings in the same compound did not show a clear enhancement of activity.